--- title: "Zilucoplan | PepTracker Pro" url: https://peptrackerpro.com/peptides/zilucoplan description: "A self-administered, once-daily subcutaneous macrocyclic peptide that inhibits complement component 5 (C5), FDA- and EMA-approved for anti-AChR-positive generalized myasthenia gravis." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This page is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # Zilucoplan High Evidence A self-administered, once-daily subcutaneous macrocyclic peptide that inhibits complement component 5 (C5), FDA- and EMA-approved for anti-AChR-positive generalized myasthenia gravis. Aliases Zilbrysq +2 more Evidence High Evidence Last Updated 2026-07-03 Reading Time 3 min ## What It Is Zilucoplan (brand name Zilbrysq, developed by UCB) is a synthetic macrocyclic peptide inhibitor of complement component 5 (C5). It belongs to a class of targeted therapeutic peptides that act on the complement cascade — part of the innate immune system — rather than on metabolic or neurotrophic pathways. Zilucoplan binds C5 with high affinity and a dual mechanism: it blocks cleavage of C5 into C5a and C5b by C5 convertase, and it also binds C5b to prevent its interaction with C6, together stopping assembly of the membrane attack complex (MAC). In anti-acetylcholine-receptor (anti-AChR) antibody-positive generalized myasthenia gravis (gMG), complement-mediated damage to the neuromuscular junction is a central driver of muscle weakness, and blocking the terminal complement pathway protects the junction. Unlike the earlier intravenous anti-C5 antibodies (eculizumab, ravulizumab), zilucoplan is a small peptide that patients self-administer as a once-daily subcutaneous injection. Its pivotal phase 3 RAISE trial (published in Lancet Neurology, 2023) randomized 174 adults with anti-AChR-positive gMG and met its primary endpoint: the least-squares mean change in MG-ADL score at week 12 was −4.39 with zilucoplan versus −2.30 with placebo (difference −2.09; p=0.0004), with consistent improvements across secondary measures (QMG, MGC). On the strength of RAISE and the RAISE-XT open-label extension, zilucoplan was approved by the U.S. FDA in October 2023 and in the EU in December 2023 for anti-AChR-positive gMG in adults. Because terminal complement inhibition raises the risk of serious meningococcal (Neisseria meningitidis) infection, it carries a boxed warning, requires meningococcal vaccination, and is dispensed under a risk-management program. In 2026 zilucoplan continues to draw attention as one of the first self-injectable peptide complement inhibitors, with ongoing long-term extension data and a 2026 medicinal-chemistry account of its discovery; it is an approved drug, not a research chemical. Also known as: Zilbrysq, RA101495, UCB7665 ## Regulatory Status FDA-approved (2023) for anti-AChR-positive generalized myasthenia gravis; boxed warning Zilucoplan (Zilbrysq, UCB) was approved by the U.S. FDA in October 2023 and by the EMA in December 2023 for the treatment of generalized myasthenia gravis in adults who are anti-acetylcholine-receptor (anti-AChR) antibody positive. It is a prescription drug administered as a once-daily 0.3 mg/kg subcutaneous self-injection. It carries a boxed warning for serious meningococcal infections, requires meningococcal vaccination before initiation, and is available only through a restricted risk-management/REMS program. It is not a compounding-pharmacy 'research peptide.' Effective: June 2026 View FDA Source (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10925559/) ## Why Researchers Study It Zilucoplan is a landmark example of a macrocyclic peptide engineered into an approved drug for an autoimmune disease, and the first complement C5 inhibitor that patients can self-administer subcutaneously once daily rather than by intravenous infusion. It is studied as a proof of concept that peptide chemistry can deliver targeted, terminal-complement inhibition at the neuromuscular junction, and for what its real-world and long-term extension data reveal about durability, safety, and the place of complement inhibition relative to FcRn blockers and anti-C5 antibodies in generalized myasthenia gravis. ## Proposed Mechanisms - Binds complement component 5 (C5) with high affinity as a synthetic macrocyclic peptide - Blocks cleavage of C5 into the pro-inflammatory fragment C5a and into C5b by C5 convertase - Independently binds C5b to prevent its interaction with C6, adding a second block on the terminal pathway - Prevents assembly of the membrane attack complex (MAC), protecting the neuromuscular junction from complement-mediated damage - Reduces anti-AChR antibody-driven, complement-mediated destruction of acetylcholine receptors in generalized myasthenia gravis - Formulated for once-daily subcutaneous self-injection at 0.3 mg/kg ## Evidence Snapshot High Evidence Low Medium High | Study Type | Model | Outcome | Link | | --- | --- | --- | --- | | RCT (human, phase 3 — RAISE) | Anti-AChR-positive generalized myasthenia gravis — 174 adults, 0.3 mg/kg subcutaneous once daily, 12 weeks | Positive: MG-ADL change at week 12 −4.39 vs −2.30 placebo (difference −2.09; p=0.0004); QMG and MGC also improved. Lancet Neurology 2023 | Source: https://pubmed.ncbi.nlm.nih.gov/37059508/ | | Open-label extension (human — RAISE-XT) | Long-term zilucoplan in generalized myasthenia gravis | Interim analysis reported sustained MG-ADL/QMG improvement and a consistent long-term safety profile | Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11025429/ | | Regulatory review / first approval | Anti-AChR-positive gMG, adults | Approved by U.S. FDA (Oct 2023) and EMA (Dec 2023); boxed warning for meningococcal infection | Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10925559/ | | Medicinal-chemistry / discovery (2026) | Macrocyclic peptide design and optimization | Detailed account of zilucoplan's discovery as a self-administered subcutaneous C5 inhibitor. J Med Chem 2026 | Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12751008/ | ## Commonly Discussed Benefits Immune Modulation: https://peptrackerpro.com/benefits/immune-modulation Neuromuscular Function: https://peptrackerpro.com/benefits/neuromuscular-function Researching Zilucoplan? Track it, set reminders, and keep notes in the free app. Track in App (https://app.peptrackerpro.com/?add=zilucoplan) ## Safety & Cautions - Boxed warning: increases the risk of serious, life-threatening meningococcal (Neisseria meningitidis) infection - Requires meningococcal vaccination before starting and is dispensed only through a restricted risk-management/REMS program - Indicated specifically for anti-AChR antibody-positive generalized myasthenia gravis in adults — not for seronegative or MuSK-positive disease - A prescription biologic-class drug that must be used under specialist neurology supervision — not a self-experimentation research peptide - May raise the risk of other encapsulated-organism infections; injection-site reactions are common - Long-term comparative positioning versus FcRn inhibitors and anti-C5 antibodies is still being established ## Comparisons See how Zilucoplan compares to related peptides: Zilucoplan vs Ara-290: https://peptrackerpro.com/compare/zilucoplan-vs-ara-290 Zilucoplan vs Batoclimab: https://peptrackerpro.com/compare/zilucoplan-vs-batoclimab Zilucoplan vs Efgartigimod: https://peptrackerpro.com/compare/zilucoplan-vs-efgartigimod Zilucoplan vs Efzofitimod: https://peptrackerpro.com/compare/zilucoplan-vs-efzofitimod Zilucoplan vs Larazotide: https://peptrackerpro.com/compare/zilucoplan-vs-larazotide Zilucoplan vs Motixafortide (Aphexda): https://peptrackerpro.com/compare/zilucoplan-vs-motixafortide Zilucoplan vs Nipocalimab: https://peptrackerpro.com/compare/zilucoplan-vs-nipocalimab Zilucoplan vs Pegcetacoplan: https://peptrackerpro.com/compare/zilucoplan-vs-pegcetacoplan Zilucoplan vs Rozanolixizumab: https://peptrackerpro.com/compare/zilucoplan-vs-rozanolixizumab Zilucoplan vs Thymosin Alpha-1: https://peptrackerpro.com/compare/zilucoplan-vs-thymosin-alpha-1 Zilucoplan vs Zosurabalpin: https://peptrackerpro.com/compare/zilucoplan-vs-zosurabalpin Zilucoplan vs Povetacicept: https://peptrackerpro.com/compare/zilucoplan-vs-povetacicept ## Calculator Tools Use our research tools to explore dosing and reconstitution data: Reconstitution Calculator: https://peptrackerpro.com/calculators ## Citations 1. [1] Howard JF et al. — Safety and efficacy of zilucoplan in generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 2023 PubMed (https://pubmed.ncbi.nlm.nih.gov/37059508/) 2. [2] Zilucoplan: First Approval. Drugs 2024 (PMC) PubMed (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10925559/) 3. [3] Long-term safety and efficacy of zilucoplan in gMG: interim analysis of the RAISE-XT open-label extension. PMC PubMed (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11025429/) 4. [4] Zilucoplan: A Newly Approved Macrocyclic Peptide for Anti-AChR-Positive Myasthenia Gravis (review). MDPI 2024 PubMed (https://www.mdpi.com/2813-2998/3/2/18) 5. [5] Discovery of Zilucoplan: A Complement C5 Inhibitor for AChR-Positive gMG. J Med Chem 2026 (PMC) PubMed (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12751008/) 6. [6] ZILBRYSQ (zilucoplan) mechanism of action — UCB PubMed (https://www.zilbrysqhcp.com/moa) ### Keep researching in the app - Log Zilucoplan to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack Open PepTracker Pro Free: https://app.peptrackerpro.com/?add=zilucoplan Browse more peptides: https://peptrackerpro.com/peptides ## Related Peptides ### Ara-290 Medium Evidence A non-erythropoietic EPO analog studied for nerve repair and neuropathic pain conditions. Nerve Repair: https://peptrackerpro.com/benefits/nerve-repair Pain Relief: https://peptrackerpro.com/benefits/pain-relief Inflammation: https://peptrackerpro.com/benefits/inflammation Recovery: https://peptrackerpro.com/benefits/recovery View Details: https://peptrackerpro.com/peptides/ara-290 \+ Compare: https://peptrackerpro.com/compare?select=ara-290 Track in App: https://app.peptrackerpro.com/?add=ara-290 ### Batoclimab High Evidence Batoclimab (development codes IMVT-1401, RVT-1401, HBM9161, HL161) is an investigational, fully human IgG1 monoclonal antibody that blocks the neonatal Fc receptor (FcRn), developed by Immunovant/Roivant (U.S. and Canada) and Harbour BioMed (Greater China) under license from HanAll Biopharma. It is not a small synthetic peptide but a full-length antibody given as a low-volume subcutaneous injection that patients can self-administer at home. Like the approved FcRn blockers efgartigimod, nipocalimab and rozanolixizumab, it lowers circulating IgG - including pathogenic autoantibodies - but it is best known for two things the others are not: it is the FcRn blocker that generated positive Phase 3 myasthenia gravis data yet was deliberately NOT filed for U.S. approval, and it is the one whose FcRn-mediated albumin recycling blockade produces a distinctive on-target signal of lowered serum albumin and raised LDL cholesterol - the exact liability that drove its makers to a re-engineered successor, IMVT-1402. Immune Modulation: https://peptrackerpro.com/benefits/immune-modulation Neuromuscular Function: https://peptrackerpro.com/benefits/neuromuscular-function Rare Disease Treatment: https://peptrackerpro.com/benefits/rare-disease-treatment Disease Modification: https://peptrackerpro.com/benefits/disease-modification View Details: https://peptrackerpro.com/peptides/batoclimab \+ Compare: https://peptrackerpro.com/compare?select=batoclimab Track in App: https://app.peptrackerpro.com/?add=batoclimab ### Efgartigimod High Evidence Efgartigimod (efgartigimod alfa, brand names Vyvgart intravenous and Vyvgart Hytrulo subcutaneous) is a first-in-class antagonist of the neonatal Fc receptor (FcRn) developed by argenx as ARGX-113. It is not a small synthetic peptide but an engineered fragment of the human immunoglobulin G1 (IgG1) antibody - specifically the Fc portion that normally binds FcRn - modified with argenx's ABDEG technology to bind FcRn with much higher affinity than natural IgG at both neutral and acidic pH. FcRn is the salvage receptor that rescues circulating IgG from lysosomal degradation and recycles it back into the blood, giving antibodies their long half-life. By outcompeting endogenous IgG for FcRn, efgartigimod blocks that recycling and drives rapid clearance of IgG - including the pathogenic autoantibodies that cause many autoimmune diseases - typically lowering total IgG by roughly 60-70% within weeks, without reducing IgM, IgA, or albumin. It was the first FcRn blocker ever approved: FDA-approved in December 2021 (Vyvgart IV) for acetylcholine-receptor-antibody-positive generalized myasthenia gravis (gMG) on the strength of the Phase 3 ADAPT trial, followed by a subcutaneous co-formulation with recombinant hyaluronidase (Vyvgart Hytrulo) for gMG in 2023 and for chronic inflammatory demyelinating polyneuropathy (CIDP) in 2024. In May 2026 the FDA expanded the gMG label to all serotypes - including AChR-antibody-negative (seronegative) patients - based on the Phase 3 ADAPT SERON trial, making efgartigimod the first and only therapy approved across every gMG antibody subtype. It is being studied in a broad set of other IgG-driven autoimmune diseases, including primary immune thrombocytopenia, myositis, Sjogren's disease, bullous pemphigoid, and lupus nephritis. View Details: https://peptrackerpro.com/peptides/efgartigimod \+ Compare: https://peptrackerpro.com/compare?select=efgartigimod Track in App: https://app.peptrackerpro.com/?add=efgartigimod ### Efzofitimod Medium Evidence A first-in-class, intravenous immunomodulatory fusion peptide derived from histidyl-tRNA synthetase that selectively binds neuropilin-2 (NRP2) to dampen inflammation in the lung; in Phase 3 development for pulmonary sarcoidosis, an interstitial lung disease. Inflammation: https://peptrackerpro.com/benefits/inflammation Immune Support: https://peptrackerpro.com/benefits/immune-support View Details: https://peptrackerpro.com/peptides/efzofitimod \+ Compare: https://peptrackerpro.com/compare?select=efzofitimod Track in App: https://app.peptrackerpro.com/?add=efzofitimod ### Larazotide Medium Evidence A synthetic peptide tight junction regulator in clinical trials for celiac disease, designed to prevent intestinal permeability caused by gluten exposure. Gut Health: https://peptrackerpro.com/benefits/gut-health Inflammation: https://peptrackerpro.com/benefits/inflammation Immune Support: https://peptrackerpro.com/benefits/immune-support View Details: https://peptrackerpro.com/peptides/larazotide \+ Compare: https://peptrackerpro.com/compare?select=larazotide Track in App: https://app.peptrackerpro.com/?add=larazotide ### Motixafortide (Aphexda) High Evidence An FDA-approved synthetic cyclic peptide and CXCR4 antagonist (brand name Aphexda; research name BL-8040) used together with G-CSF to mobilize blood-forming stem cells for autologous transplant in multiple myeloma. In 2026 it is being actively studied as part of combination immunotherapy for pancreatic cancer. Hematology: https://peptrackerpro.com/benefits/hematology Oncology: https://peptrackerpro.com/benefits/oncology Immune Modulation: https://peptrackerpro.com/benefits/immune-modulation View Details: https://peptrackerpro.com/peptides/motixafortide \+ Compare: https://peptrackerpro.com/compare?select=motixafortide Track in App: https://app.peptrackerpro.com/?add=motixafortide ### Nipocalimab High Evidence Nipocalimab (brand name Imaavy, development code M281) is a fully human, aglycosylated, 'effectorless' IgG1 monoclonal antibody that blocks the neonatal Fc receptor (FcRn), developed by Johnson & Johnson (Janssen). Like efgartigimod it lowers circulating immunoglobulin G (IgG) - including the pathogenic autoantibodies that drive many autoimmune diseases - by occupying FcRn and preventing it from recycling IgG back into the blood, so unrescued IgG is routed to the lysosome and degraded, typically cutting total IgG by roughly 65-75% while sparing IgM, IgA, complement, and albumin. Unlike efgartigimod's engineered Fc fragment, nipocalimab is a full-length monoclonal antibody engineered to be aglycosylated and effectorless (it does not trigger ADCC or complement-dependent cytotoxicity), and it is dosed as a maintenance intravenous infusion for continuous IgG suppression rather than in short cycles. The FDA approved Imaavy on April 30, 2025 for generalized myasthenia gravis (gMG) in anti-AChR-antibody-positive and anti-MuSK-antibody-positive patients aged 12 and older - making it the first FcRn blocker approved for adolescents and the first to explicitly cover MuSK-positive disease - on the strength of the Phase 3 Vivacity-MG3 trial. It has since generated positive data across a striking breadth of IgG-mediated conditions: Sjogren's disease (Phase 2 DAHLIAS), rheumatoid arthritis, warm autoimmune hemolytic anemia (wAIHA), and - uniquely among FcRn blockers - maternal-fetal alloimmune disease, where it is being developed to treat hemolytic disease of the fetus and newborn (HDFN) by crossing the placenta to protect the fetus. In April 2026 the FDA granted Priority Review to nipocalimab for wAIHA, positioning it as a potential first approved therapy for that condition. View Details: https://peptrackerpro.com/peptides/nipocalimab \+ Compare: https://peptrackerpro.com/compare?select=nipocalimab Track in App: https://app.peptrackerpro.com/?add=nipocalimab ### Pegcetacoplan High Evidence A PEGylated cyclic-peptide inhibitor of complement component 3 (C3) built from two compstatin (Cp05) peptide domains bridged by a 40-kDa PEG chain; marketed as Empaveli/Aspaveli (subcutaneous, for paroxysmal nocturnal hemoglobinuria and, since July 2025, C3 glomerulopathy and primary IC-MPGN) and Syfovre (intravitreal, for geographic atrophy in age-related macular degeneration). It is one of the few complement-targeting therapeutic peptides to reach the market. Immune Support: https://peptrackerpro.com/benefits/immune-support Inflammation: https://peptrackerpro.com/benefits/inflammation View Details: https://peptrackerpro.com/peptides/pegcetacoplan \+ Compare: https://peptrackerpro.com/compare?select=pegcetacoplan Track in App: https://app.peptrackerpro.com/?add=pegcetacoplan ### Rozanolixizumab High Evidence Rozanolixizumab (brand name Rystiggo, development code UCB7665) is a humanized IgG4 monoclonal antibody that blocks the neonatal Fc receptor (FcRn), developed by UCB. Like efgartigimod and nipocalimab it lowers circulating immunoglobulin G (IgG) - including the pathogenic autoantibodies that drive many autoimmune diseases - by binding FcRn and preventing it from recycling IgG back into the blood, so unrescued IgG is routed to the lysosome and degraded, typically cutting total IgG by roughly 70-80% while sparing IgM, IgA, complement, and albumin. Unlike efgartigimod's engineered Fc fragment, rozanolixizumab is a full-length humanized antibody, and unlike nipocalimab's intravenous infusion it is given as a rapid subcutaneous infusion (including via an on-body delivery device), typically in weekly cycles that are repeated based on clinical response rather than continuously. The FDA approved Rystiggo on June 27, 2023 for generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine-receptor (AChR) antibody-positive or anti-muscle-specific-tyrosine-kinase (MuSK) antibody-positive - making it the first therapy ever approved to treat both of those gMG subtypes - on the strength of the Phase 3 MycarinG trial. It has since been studied across other IgG-mediated diseases, including chronic inflammatory demyelinating polyneuropathy (CIDP), where it did not show meaningful benefit and was not advanced to Phase 3, and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), primary immune thrombocytopenia (ITP), and other autoantibody conditions where development continues. The European Medicines Agency approved rozanolixizumab in January 2024 and the UK MHRA in March 2024. View Details: https://peptrackerpro.com/peptides/rozanolixizumab \+ Compare: https://peptrackerpro.com/compare?select=rozanolixizumab Track in App: https://app.peptrackerpro.com/?add=rozanolixizumab ### Thymosin Alpha-1 High Evidence A thymic peptide approved in some countries for immune modulation, studied for viral infections and cancer adjunct therapy. Immune Support: https://peptrackerpro.com/benefits/immune-support Longevity: https://peptrackerpro.com/benefits/longevity Inflammation: https://peptrackerpro.com/benefits/inflammation View Details: https://peptrackerpro.com/peptides/thymosin-alpha-1 \+ Compare: https://peptrackerpro.com/compare?select=thymosin-alpha-1 Track in App: https://app.peptrackerpro.com/?add=thymosin-alpha-1 ### Zosurabalpin Medium Evidence A first-in-class tethered macrocyclic peptide antibiotic that kills carbapenem-resistant Acinetobacter baumannii (CRAB) by blocking the bacterium's lipopolysaccharide (LPS) transporter, now advancing into a global Phase 3 trial. Antimicrobial: https://peptrackerpro.com/benefits/antimicrobial View Details: https://peptrackerpro.com/peptides/zosurabalpin \+ Compare: https://peptrackerpro.com/compare?select=zosurabalpin Track in App: https://app.peptrackerpro.com/?add=zosurabalpin ### Povetacicept High Evidence Povetacicept (development code ALPN-303) is an investigational, once-monthly, subcutaneously injected recombinant fusion protein that simultaneously blocks two B-cell survival signals - BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand). It is built from an engineered ('variant') form of the natural TACI receptor's extracellular domain fused to an antibody (IgG) Fc region, so it acts as a high-affinity decoy that soaks up both BAFF and APRIL before they can reach their receptors on B cells and plasma cells. Because BAFF and APRIL drive the maturation and antibody production of the immune cells behind many autoantibody- and immune-complex-mediated diseases, povetacicept is being developed for B-cell-driven autoimmune conditions - most prominently IgA nephropathy (IgAN), where APRIL fuels the production of the galactose-deficient IgA1 that damages the kidney. Originated by Alpine Immune Sciences (acquired by Vertex Pharmaceuticals in 2024), povetacicept has received FDA Breakthrough Therapy Designation for IgAN; in March 2026 the Phase 3 RAINIER trial reported a positive prespecified Week 36 interim analysis (a ~52% reduction in urine protein-to-creatinine ratio from baseline and a ~50% reduction versus placebo), and in June 2026 the FDA accepted a Biologics License Application for accelerated approval with a target action date of November 30, 2026. Povetacicept is an experimental biologic given only in clinical trials; it is not a supplement, nootropic, or research chemical. renal: https://peptrackerpro.com/benefits/renal autoimmune: https://peptrackerpro.com/benefits/autoimmune Disease Modification: https://peptrackerpro.com/benefits/disease-modification B-cell-modulation: https://peptrackerpro.com/benefits/B-cell-modulation View Details: https://peptrackerpro.com/peptides/povetacicept \+ Compare: https://peptrackerpro.com/compare?select=povetacicept Track in App: https://app.peptrackerpro.com/?add=povetacicept ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Zilucoplan", "description": "A self-administered, once-daily subcutaneous macrocyclic peptide that inhibits complement component 5 (C5), FDA- and EMA-approved for anti-AChR-positive generalized myasthenia gravis.", "url": "https://peptrackerpro.com/peptides/zilucoplan", "lastReviewed": "2026-07-03", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Zilucoplan", "item": "https://peptrackerpro.com/peptides/zilucoplan" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People researching complement (C5) inhibitors and macrocyclic peptide drugs?", "acceptedAnswer": { "@type": "Answer", "text": "Zilucoplan is a research peptide studied in preclinical models. A self-administered, once-daily subcutaneous macrocyclic peptide that inhibits complement component 5 (C5), FDA- and EMA-approved for anti-AChR-positive generalized myasthenia gravis." } }, { "@type": "Question", "name": "Patients and clinicians following generalized myasthenia gravis treatment options?", "acceptedAnswer": { "@type": "Answer", "text": "Zilucoplan is a research peptide studied in preclinical models. A self-administered, once-daily subcutaneous macrocyclic peptide that inhibits complement component 5 (C5), FDA- and EMA-approved for anti-AChR-positive generalized myasthenia gravis." } }, { "@type": "Question", "name": "Those interested in approved, targeted therapeutic peptides beyond the metabolic and longevity classes?", "acceptedAnswer": { "@type": "Answer", "text": "Zilucoplan is a research peptide studied in preclinical models. A self-administered, once-daily subcutaneous macrocyclic peptide that inhibits complement component 5 (C5), FDA- and EMA-approved for anti-AChR-positive generalized myasthenia gravis." } } ] } ] ```